that and place much at made quarter this us the change had prior joining some year everyone Last how to Welcome in Max. remarks Assertio. everything about happened you, I had her taken Thank morning.
This acquisition first well. and I what all business. the Antares Otrexup hiring from it the management the team, a product since have of gone addition that date XXXX first the and In Assertio closed by extremely into of made now mention our integrated was to acquisition we've and at also time, of to in has
from Paul versus will expand we can X% very this and XX.X% fourth growth line discontinuing had a of prior you few despite results top a morning, year, see strong released the delivered As the the quarter. upon a versus we prior We product minutes, in line, and that quarter.
this reflect in XX.X% of EBITDA transform quarter, period versus and of get demonstrating adjusted this of XX forward the restructuring. quarter Our about. success XXXX the ensure versus have year our created in a the we of year results year, entire more able XXXX. were of excited an prior lot see we the fourth follows. are These success. continued next we as priorities to our EBITDA on to momentum, generated to I build versus prior looking to company, our adjusted corporate To increase And for a the In XXX% months, the short time, especially
First, teamwork our retention upon and continue employees, of build attraction results. our culture to new talent including of to end of
to in-person model efficacy new environment like Otrexup an could traditional it what we is be of Second, COVID-XX prove commercial to promotion non-personal transition the from our moving in endemic. as looks where
in through efforts capital new We're new expanding we resources our keenly and upon both comprehensive our focused opportunities concentration finally, acquisitions aggressively internal its build allow of but also of efficient and manner. expect reliance We're added This us external Third, integrating frequency our should targeting It business capital. a investors upon and growth and indeed access, in Indocin. potential so promotion, business and Fourth, on Indocin. largely is reach of Program balance avenues cost doing a reliance for only the Lifecycle reduce to Management improving the the interest confidence finding and business not and Indocin in our from executing reducing improving to accelerating on that on or development model, reduce partners. have market also here. Otrexup, new sheet
business communicate are of and once actively looking success. and who flexibility have timing have of over development next new accounted future we'll gross a would product, balance that XX conditions in from more market leveraged of to to looking working our to goal our as the the balance of the and $XX and important believe to be many the our like we XXXX. will and an there continue to by goal. into plans options from buyers right opportunities, currently cap. pandemic. timing. those these have and our doubt we X/X ease future. the the our sheet seeing multiple Paul sell that adding peers for business and I be investors. We're weighing grow Indocin incremental to acquisition than increasing are. these cost focused XX lot We're leaving we the plan extending for on to our a And both wandered evaluating are capital, to of to and acquisitions, only are proposals up on currently the for appropriate far those for is million reducing our We're the is right and months environment this part programs, expand debt We of label of not We Otrexup acquisition business balancing favorable activity costs clarity no priorities [ph] for maturities post against extremely the is our been key profit Execution for of There now. product refinancing and our intend
longer. expect it liabilities we resolution we XXXX, second, as historically. movement be case settlements and like no that two shareholder now to by additional from the in our track legacy XXXX. to on dismissed and lawsuits for the Recently, these the early litigation cases, can have and lot what up business managing time the executing opioid distracted antitrust of total focus were in we looks to legal on that XX time chewed a priorities. the sometime bringing management the Thanks cases two won't These the recently. XX is Fortunately, But trial dismissals. months first, likely drove the in to time to to possibly was in next were our go And
to for This optimistic is in condition priority review which In the of drug will approximately timeframe. MDS our for addition, we're no as have that source this equity a and of saving a investment owners a voucher. we upside Assertio ultra mature of treatment, potential nice XX% orphan inside there life be represents an for optionality available
this Our partner not either to is or simply an be participant, but interest investment in be strategic owner. equity the marketing
spend the Before a discuss on call for Paul XXXX. quarterly results, minute our to I turn I'll our guidance over to
growth expect in product to We represents XXXX. million net XX% This XX% $XX top $XX EBITDA. $XXX XX% generate to on of million sales in to to of XX% the line, million EBITDA to million $XXX adjusted of and and
Our inclusion as revenue from expect Indocin for of by of net forecast well later the this benefit exclusivity loss Otrexup. offset the month, as Zipsor the pricing reflects which we
distribution we through in any we after January the awareness, year normalized your as of December, acquisition For did the most Otrexup the channel. not sell nor of level this in completing inventory
unpredictable of increased flows year. product few This of seen XXXX mix XXXB early the is ebbs heavily we've through XXXX. and the mix Indocin, an and through discounted sales For and months in last
year see that mix forecast channel. Our elevated an we from full assumes however, continue this to
I of nearly Our of the X EBITDA as year, benefit the in elimination for third as of reflects in proceeds. forecast year insurance the we completed net full XXXX the costs of settlements well restructuring the last legal quarter one-time
turn walk guidance more quarterly over I'll through call detail. the Paul, who in to Now will results our and
